Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

hives

- PMLiVE

InflaRx reports positive phase 2 results for HS and CSU treatments

Topline results demonstrated treatment efficacy for both conditions

- PMLiVE

Sanofi/Regeneron’s Dupixent granted FDA approval for chronic spontaneous urticaria

More than 300,000 people in the US are living with uncontrolled cases of the inflammatory skin disease

- PMLiVE

Novartis gains rights to Kyorin’s chronic spontaneous urticaria candidate in deal worth $830m

The common skin condition affects approximately 40 million people worldwide

- PMLiVE

Sanofi/Regeneron announce positive late-stage results for Dupixent in chronic spontaneous urticaria

Detailed results from the confirmatory trial will be submitted to the FDA later this year

- PMLiVE

Novartis shares promising phase 3 results for BTK inhibitor in chronic hives

Around 60% of chronic spontaneous urticaria patients are uncontrolled by H1-antihistamines

- PMLiVE

Novartis reveals positive efficacy data for Xolair follow-up

Next-generation treatment is more effective than current therapy

Novartis plans digital therapeutics for schizophrenia and MS

Will work with Pear Therapeutics on a prescription software range

- PMLiVE

NICE wants more info on Novartis’ Xolair in chronic hives

Says company must provide more data on the drug's effectiveness

- PMLiVE

Novartis’ dermatology plans advance with Xolair approval

Green light for use in chronic spontaneous urticaria

- PMLiVE

Novartis’ omalizumab effective in chronic skin disease

Study backs extended use of asthma treatment Xolair

- PMLiVE

Novartis’ omalizumab on track for filing in serious skin disease

Is active ingredient in asthma drug Xolair

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links